胃复方干预治疗脾虚瘀毒型中晚期胃癌临床研究

Clinical Study on the Intervention of Gastric Compound for Patients with Middle-late Gastric Cancer of Spleen Deficiency and Stasis Toxin

目的探讨胃复方干预治疗对脾虚瘀毒型中晚期胃癌患者生活质量的影响。方法将90例脾虚瘀毒型中晚期胃癌患者随机分为中药联合化疗组、化疗组、中药组,每组30例。中药联合化疗组予胃复方加化疗,化疗组予化疗加安慰剂,中药组予胃复方治疗。观察3组患者QLQ-C30生活质量量表积分、Piper癌因疲乏量表积分、中医证候评分、卡氏评分改变情况及消化道、骨髓抑制毒副反应,评价胃复方对患者生活质量的影响。结果中药联合化疗组QLQ-C30量表积分、癌因疲乏程度、中医证候、体力状况改善情况优于中药组及化疗组,差异均有统计学意义(P<0.05);中药组癌因疲乏程度、中医证候改善情况优于化疗组,差异均有统计学意义(P<0.05);中药联合化疗组骨髓抑制及消化道毒副反应较化疗组轻,2组比较差异有统计学意义(P<0.01)。结论胃复方干预治疗能改善脾虚瘀毒型中晚期胃癌患者生活质量,减轻化疗所致骨髓抑制及消化道毒副反应。

Objective To evaluate the effect of gastric compound on patients with middle-late gastric cancer of spleen deficiency and stasis toxin. Methods Ninety patients with middle-late gastric cancer of spleen deficiency and stasis toxin were randomly divided into combined group, chemotherapy group, and gastric compound group, 30 cases in each group. Patients in the combined group were treated with gastric compound and chemotherapy;patients in the chemotherapy group were treated with placebo;patients in the gastric compound group were treated with gastric compound. The changes of QLQ-C30 scale integral, fatigue scale intergral, TCM symptom intergral, Karnofsky integral, and toxic and side effects of digestive tract and myelosuppression were observed to evaluate the effect of gastric compound on quality of life in patients. Results The changes of QLQ-C30 scale integral, fatigue scale intergral, TCM symptom intergral, Karnofsky intergal in combined group were better than those in chemotherapy group and gastric compound group, with statistical significance （P〈0.05）. The changes of fatigue scale intergral and TCM symptom intergral in gastric compound group were better than those in chemotherapy group, with statistical significance （P〈0.05）. The myelosuppression and toxic and side effects of digestive tract of combined group was lighter than those of chemotherapy group, with statistical significance （P〈0.01）. Conclusion Gastric compound combined with chemotherapy can improve quality of life in patients with middle-late gastric cancer of spleen deficiency and stasis toxin, and reduce myelosuppression and toxic and side effects of digestive tract.